An update on the histological subtypes of hepatocellular carcinoma

Abstract

Hepatocellular carcinoma (HCC) is one of the top-ranking cancers worldwide and in Southeast Asia. The high propensity for tumor recurrence, distant metastasis and chemoresistance remain major hurdles in the treatment of HCC. With advances on genetics and genomics research, molecular targeted therapies are emerging as a hope for better disease control. On the histological perspective, microscopic review of clinical samples has led to subclassification of HCC and establishment of new entities. In this review, latest understanding on macrotrabecular-massive HCC, steatohepatitic HCC, lymphocyte-rich HCC, scirrhous HCC, fibrolamellar carcinoma and combined hepatocellular-cholangiocarcinoma will be discussed, emphasizing on the clinical relevance of these pathological entities. Further delineation of the histological, immunohistochemical, molecular and biological phenotypes of primary liver cancer would to further enhance an integrated morphological-molecular classification that better predicts clinical outcome and guides clinical management.

Keywords

Liver cancer / subtype / histology

References

[1] Roncalli M,Di Tommaso L.Histopathological classification of hepatocellular carcinoma..Dig Liver Dis.2010;42 supp-S3:S228-34

[2] Bosman FT,Hruban RH.WHO classification of tumours of the digestive system.2019;5th ed.GenevaInternational agency for Research on Cancer229

[3] Ziol M,Amaddeo G,Nault JC.Macrotrabecular-massive hepatocellular carcinoma: a distinctive histological subtype with clinical relevance..Hepatology2018;68:103-12

[4] Okabe H,Yamashita YI,Hayashi H.Histological architectural classification determines recurrence pattern and prognosis after curative hepatectomy in patients with hepatocellular carcinoma..PLoS One2018;13:e0203856 PMCID:PMC6138409

[5] Jeon Y,Taddei T,Zhang X.Macrotrabecular hepatocellular carcinoma: an aggressive subtype of hepatocellular carcinoma..Am J Surg Pathol2019;43:943-8

[6] Rhee H,Kim HY,Park YN.Hepatocellular carcinoma with irregular rim-like arterial phase hyperenhancement: more aggressive pathologic features..Liver Cancer2019;8:24-40 PMCID:PMC6388566 [Available on 2020-02-01]

[7] Calderaro J,Nguyen CT,Caruso S.ESM1 as a marker of macrotrabecular-massive hepatocellular carcinoma..Clin Cancer Res2019;25:5859-65

[8] Calderaro J,Imbeaud S,Letouze E.Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification..J Hepatol2017;67:727-38

[9] Boyault S,de Reynies A,Rebouissou S.Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets..Hepatology2007;45:42-52

[10] Salomao M,Brown RS Jr,Lefkowitch JH.Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH..Am J Surg Pathol2010;34:1630-6

[11] Salomao M,Vaughan R,Lefkowitch JH.The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis..Hum Pathol2012;43:737-46

[12] Tan PS,Goossens N,Huang T.Clinicopathological indices to predict hepatocellular carcinoma molecular classification..Liver Int2016;36:108-18 PMCID:PMC4674393

[13] Jain D,Kumaran V.Steatohepatitic hepatocellular carcinoma, a morphologic indicator of associated metabolic risk factors: a study from India..Arch Pathol Lab Med2013;137:961-6

[14] Lee JS,Kim H,Koh MJ.Tumor stroma with senescence-associated secretory phenotype in steatohepatitic hepatocellular carcinoma..PLoS One2017;12:e0171922 PMCID:PMC5342190

[15] Yeh MM,Torbenson M.Steatohepatitic variant of hepatocellular carcinoma in the absence of metabolic syndrome or background steatosis: a clinical, pathological, and genetic study..Hum Pathol2015;46:1769-75

[16] Taniai M,Tobari M,Tokushige K.Clinicopathological investigation of steatohepatitic hepatocellular carcinoma: a multicenter study using immunohistochemical analysis of adenoma-related markers..Hepatol Res2018;48:947-55

[17] Ando S,Hayashi A.β-catenin alteration is rare in hepatocellular carcinoma with steatohepatitic features: immunohistochemical and mutational study..Virchows Arch2015;467:535-42

[18] Hoshida Y,Kobayashi M,Brunet JP.Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma..Cancer Res2009;69:7385-92 PMCID:PMC3549578

[19] Chan AW,Pan Y,Wong GL.Lymphoepithelioma-like hepatocellular carcinoma: an uncommon variant of hepatocellular carcinoma with favorable outcome..Am J Surg Pathol2015;39:304-12

[20] Patel KR,Vaccharajani N,Brunt EM.Characterization of inflammatory (lymphoepithelioma-like) hepatocellular carcinoma: a study of 8 cases..Arch Pathol Lab Med2014;138:1193-202

[21] Wada Y,Kutami R,Kojiro M.Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration..Hepatology1998;27:407-14

[22] Chen CJ,Huang SF.Lymphoepithelioma-like hepatocellular carcinoma..Chang Gung Med J2007;30:172-7

[23] Cacciato Insilla A,Pollina LE,Coletti L.Lymphoepithelioma-like hepatocellular carcinoma: case report and review of the literature..World J Gastroenterol2015;21:10468-74 PMCID:PMC4579894

[24] Shinoda M,Tsujikawa H,Itano O.Lymphoepithelioma-like hepatocellular carcinoma: a case report and a review of the literature..World J Surg Oncol2013;11:97 PMCID:PMC3654885

[25] Park HS,Kim YK,Moon WS.Hepatocellular carcinoma with massive lymphoid infiltration: a regressing phenomenon?.Pathol Res Pract2009;205:648-52

[26] Si MW,Lauwers GY,Furman J.Hepatocellular lymphoepithelioma-like carcinoma associated with epstein barr virus: a hitherto unrecognized entity..Diagn Mol Pathol2004;13:183-9

[27] Shirabe K,Maeda T,Kuwano H.A long-term surviving patient with hepatocellular carcinoma including lymphocytes infiltration - a clinicopathological study..Hepatogastroenterology1995;42:996-1001

[28] Emile JF,Sebagh M,Falissard B.Hepatocellular carcinoma with lymphoid stroma: a tumour with good prognosis after liver transplantation..Histopathology2000;37:523-9

[29] Wei J,Wang C.Lymphoepithelioma-like hepatocellular carcinoma without Epstein-Barr virus infection: a case report and a review of the literature..Indian J Pathol Microbiol2015;58:550-3

[30] An SL,Zheng YL,Wu F.Primary lymphoepithelioma-like hepatocellular carcinoma: report of a locally advanced case and review of literature..Int J Clin Exp Pathol2015;8:3282-7 PMCID:PMC4440162

[31] Labgaa I,Ward SC.Lymphoepithelioma-like carcinoma in liver..Am J Pathol2017;187:1438-44

[32] Chan AW,Chong CC,Chow C.Genomic landscape of lymphoepithelioma-like hepatocellular carcinoma..J Pathol2019;249:166-72

[33] Harding JJ,Armenia J,Albano M.Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies..Clin Cancer Res2019;25:2116-26 PMCID:PMC6689131

[34] Calderaro J,Amaddeo G,Charpy C.Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features..Hepatology2016;64:2038-46

[35] Seok JY,Woo HG,Kwon SM.A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma-like gene expression trait and epithelial-mesenchymal transition..Hepatology2012;55:1776-86

[36] Farooq A,Paredes AZ,Tsilimigras DI.Outcomes of patients with scirrhous hepatocellular carcinoma: insights from the national cancer database..J Gastrointest Surg2019;Epub ahead of print

[37] Lee JH,Gwak GY,Koh KC.Clinicopathologic characteristics and long-term prognosis of scirrhous hepatocellular carcinoma..Dig Dis Sci2012;57:1698-707

[38] Fujii T,Harada K,Masuda S.Participation of liver cancer stem/progenitor cells in tumorigenesis of scirrhous hepatocellular carcinoma - human and cell culture study..Hum Pathol2008;39:1185-96

[39] Okamura N,Shibuya A,Okayasu I.Cellular and stromal characteristics in the scirrhous hepatocellular carcinoma: comparison with hepatocellular carcinomas and intrahepatic cholangiocarcinomas..Pathol Int2005;55:724-31

[40] Sugiki T,Taka K.Specific characteristics of scirrhous hepatocellular carcinoma..Hepatogastroenterology2009;56:1086-9

[41] Kim SH,Lee WJ,Park CK.Scirrhous hepatocellular carcinoma: comparison with usual hepatocellular carcinoma based on CT-pathologic features and long-term results after curative resection..Eur J Radiol2009;69:123-30

[42] Edmondson HA.Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood..AMA J Dis Child1956;91:168-86

[43] Craig JR,Edmondson HA.Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features..Cancer1980;46:372-9

[44] Eggert T,Duffy A,Greten TF.Fibrolamellar hepatocellular carcinoma in the USA, 2000-2010: a detailed report on frequency, treatment and outcome based on the surveillance, epidemiology, and end results database..United European Gastroenterol J2013;1:351-7 PMCID:PMC4040774

[45] Torbenson M.Fibrolamellar carcinoma: 2012 update..Scientifica (Cairo)2012;2012:743790 PMCID:PMC3820672

[46] Choi WT,Kakar S.Immunohistochemical approach for the diagnosis of a liver mass on small biopsy specimens..Hum Pathol2017;63:1-13

[47] Mayo SC,Nathan H,Herman JM.Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma: a national perspective..J Am Coll Surg2014;218:196-205 PMCID:PMC4596238

[48] Honeyman JN,Robine N,Darcy DG.Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma..Science2014;343:1010-4 PMCID:PMC4286414

[49] Engelholm LH,Serra D,Johansen JV.CRISPR/Cas9 engineering of adult mouse liver demonstrates that the dnajb1-prkaca gene fusion is sufficient to induce tumors resembling fibrolamellar hepatocellular carcinoma..Gastroenterology2017;153:1662-73.e10 PMCID:PMC5801691

[50] Kastenhuber ER,Houlihan SL,Baslan T.DNAJB1-PRKACA fusion kinase interacts with beta-catenin and the liver regenerative response to drive fibrolamellar hepatocellular carcinoma..Proc Natl Acad Sci U S A2017;114:13076-84 PMCID:PMC5740683

[51] Turnham RE,Kenerson HL,Golkowski M.An acquired scaffolding function of the DNAJ-PKAc fusion contributes to oncogenic signaling in fibrolamellar carcinoma..Elife2019;8:e44187 PMCID:PMC6533061

[52] Brunt E,Clavien PA,Goodman Z.cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation..Hepatology2018;68:113-26 PMCID:PMC6340292

[53] Gigante E,Bertin C,Bouattour M.Combining imaging and tumor biopsy improves the diagnosis of combined hepatocellular-cholangiocarcinoma..Liver Int2019;

[54] Mihara Y,Ogasawara S,Fukushima H.Malic enzyme 1 is a potential marker of combined hepatocellular cholangiocarcinoma, subtype with stem-cell features, intermediate-cell type..Hepatol Res2019;49:1066-75

[55] Garancini M,Pagni F,Roman S.Combined hepatocellular-cholangiocarcinoma: a population-level analysis of an uncommon primary liver tumor..Liver Transpl2014;20:952-9

[56] He C,Cai Z.Competing risk analyses of overall survival and cancer-specific survival in patients with combined hepatocellular cholangiocarcinoma after surgery..BMC Cancer2019;19:178 PMCID:PMC6391817

[57] De Vito C,Ross P,Quaglia A.Histological heterogeneity in primary and metastatic classic combined hepatocellular-cholangiocarcinoma: a case series..Virchows Arch2017;471:619-29

[58] Joseph NM,Umetsu SE,Kelley RK.Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma..J Pathol2019;248:164-78

[59] Bosman FT,Hruban RH.WHO classification of tumours of the digestive system.2010;Fourth edition ed.International agency for research on cancer

[60] Moeini A,Zhang Z,Stueck A.Mixed hepatocellular cholangiocarcinoma tumors: cholangiolocellular carcinoma is a distinct molecular entity..J Hepatol2017;66:952-61

[61] Balitzer D,Ferrell L,Jain D.Immunohistochemical and molecular features of cholangiolocellular carcinoma are similar to well-differentiated intrahepatic cholangiocarcinoma..Mod Pathol2019;32:1486-94

[62] Audard V,Elie C,Audebourg A.Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations..J Pathol2007;212:345-52

[63] Calderaro J,Paradis V.Molecular and histological correlations in liver cancer..J Hepatol2019;71:616-30

[64] Kurebayashi Y,Tsujikawa H,Maehara J.Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification..Hepatology2018;68:1025-41